E-Cigarette Summit 2013
The Royal Society, London, UK, 12th November 2013

The full transcript of the event in now available to download here.
The event programme is available to download here.

Days
Hours
Minutes
Register

The E-cigarette Summit

The E-Cigarette Summit will take place at the Royal Society, London on the 12th November 2013 and will provide a vital and timely meeting for scientists, policymakers, public health professionals and e-cigarette stakeholders to come together and debate the future of e-cigarettes in context of health, efficacy and regulation.

E-cigarettes are a relatively new phenomenon – the result of a consumer led revolution – which has grown rapidly, with sales doubling annually for the last 4 years. Currently there are an estimated 7 million users across Europe and over 1.3 million in the UK alone.

The issue of how to regulate and manage the proliferation of e-cigarettes continues to divide policy makers, health campaigners and health professionals alike. With some countries moving towards an out-right ban and others looking to regulate e-cigarettes as medical products; the future is far from clear. So, are e-cigarettes a backward step in the fight against smoking or the single greatest transformative public health phenomenon? Whichever side of the debate you fall on, it is without doubt vital that all considerations are explored before decisions are taken.

The E-Cigarette Summit will provide a timely opportunity for all stakeholders to debate and examine the critical issues and the future of e-cigarettes. The Summit and will include high level briefings from leading experts on safety and efficacy, public health and regulation. The morning briefings will be followed by moderated open floor discussions which will allow key questions to be asked to a panel of experts and explored in a balanced and objective environment.


Key topics

  • What is known about e-cigarettes and what are the drivers behind their rapid rise in popularity?
  • Will e-cigarettes “re-normalise” smoking and act as a gateway in to tobacco use for a new generation?
  • How safe are e-cigarettes and what evidence is available to support their efficacy?
  • What will the impact of the EU Tobacco Directive be for current and future users?
  • Will medical regulation deliver a safer and more effective product?
  • What are the concerns that medical regulation will address in e-cigarette usage, marketing and availability?
  • Are there alternative regulatory frameworks that should or could be considered?
  • What are the potential consequences if e-cigarettes remain a consumer product?

What is at stake?

Smoking is the biggest single cause of preventable death in the developed world, and causes more than 5 million deaths per year with trends suggesting that tobacco use will result in more than 8 million deaths annually by 2030.

The devastating effect of a lifetime addiction to smoking cannot be underestimated, with up to two thirds of all lifetime smokers dying from smoking related diseases and many more suffering a seriously compromised quality of life. It is well recognised that the most damaging health impacts are caused by smoking tobacco products, rather than the consumption of nicotine.

Despite these known risks, tobacco products and cigarettes remain readily available. This fact makes the decision to regulate e-cigarettes – which are estimated to be between 99% and 95% safer – highly controversial and has divided opinion amongst health campaigners and policy makers.

So are e-cigarettes a backward step in the fight against smoking or the single greatest transformative public health phenomenon? Whichever side of the debate you fall on, it is without doubt vital that all considerations are explored before decisions are taken that could have such far reaching implications.


Who Should Attend?

The E-Cigarette Summit will provide a timely opportunity for all stakeholders to debate and explore the future of e-cigarettes, and will include high-level panel debates from opposing perspectives to ensure a balanced and objective debate.  In particular, this event will be relevant to:

In particular, this event will be relevant to:

  • Legislators and policy advisors
  • Health providers, health charities and health practitioners
  • Public health professionals
  • Scientific community with interests in tobacco harm reduction
  • Medical and health professionals
  • E-cigarette industry stakeholders

Programme
More Info
SAFETY AND EFFICACY - MORNING BRIEFINGS

08.30 – 09:00 Registration and refreshments

09.00 – 09.10 Welcome and introductions from the Chair

Prof Ann McNeillProf Ann McNeill – Professor of Tobacco Addiction, UK Centre for Tobacco Control and Alcohol Studies, King’s College London

09.10 – 09.30 Morning briefing

E-cigarettes: What are they and are they effective?
Lynne DawkinsDr Lynne Dawkins – Senior Lecturer, School of Psychology, University of East London
More Info

09.30 – 09.55 Morning briefing

How many people are using electronic cigarettes, who are they and what benefits are they getting: an analysis of data from the Smoking Toolkit Study
Prof. Robert West Prof Robert West – Professor of Health Psychology & Director of Tobacco Studies, Cancer Research UK
More Info

09.55 – 10.20 Morning briefing

Nicotine safety in the context of e-cigarette use and tobacco dependence

Dr Jacques Le HouezecDr Jacques Le Houezec – Consultant in Public Health, Tobacco dependence. Amzer Glas, Rennes, France
More Info

10.20 – 10.45 Morning briefing

Do electronic cigarettes pose health risks to users?
Dr Konstantinos Farsalinos Dr Konstantinos Farsalinos – Researcher, Onassis Cardiac Surgery Center, University Hospital Gathuisberg
More Info

10.45 – 11.10 Open floor Q&A

Are e-cigarettes safe?  Open floor questions and answers.
Chair: Prof Ann McNeill

11.10 – 11.30 Morning Break: Coffee and networking

REGULATION AND PUBLIC HEALTH - MORNING BRIEFINGS

11.30 – 11.55 Morning briefing

Proposed changes to how e-cigarettes are regulated: EU and UK context
Linda BauldProf Linda Bauld, Professor of Health Policy, University of Stirling and UKCTAS
More Info

11.55 – 12.20 Morning briefing

Regulation – when less is more
Clive BatesClive Bates – Public Health Commentator
More Info

12.20 – 12.45 Morning briefing

Summary of the MHRA proposed regulation of e-cigarettes
jeremy meanJeremy Mean – Group Manager, Access & Information for Medicines & Standards, MHRA
More Info

12.45 – 13.10 Morning briefing

How e-cigarettes should be regulated
Prof Jean Francois EtterProf Jean Francois Etter – Professor of Public Health, University of Geneva
More Info

13.10 – 13.35 Open floor Q&A

Is medical regulation the best way forward? Open floor questions and answers
Chair: Prof Ann McNeill

13.35 – 14.20 Lunch and networking

AFTERNOON DISCUSSIONS - CONTROVERSIES AND OPINIONS

14.20 – 14.40 Afternoon briefing

E-Cigarettes a disruptive public health phenomenon:
Ethics, risk and the precautionary principle

Antoine FlahaultProf Antoine Flahault, MD, PhD – Professor of Public Health, Descartes School of Medicine, Sorbonne Paris Cité, France

14.40 – 15.30 Afternoon discussion

Will medical regulation of e-cigarettes result in better quality and safer products
Expert panel: Prof Robert West, Clive Bates, Deborah Arnott (ASH), Prof Jean Francois Etter, Dr Jacques Le Houezec, Jeremy Mean (MHRA)
Chair: Prof Ann McNeill
More Info

15.30 – 15.50 Afternoon break: Coffee and networking

15.50 – 16.10 Afternoon briefing

Harm reduction, the profit motive and tobacco industry tactics – Why caution is necessary
Deborah Arnott – Chief Executive Officer, Action on Smoking (ASH)

16.10 – 17.00 Afternoon discussion

Are e-cigarettes a backward step in the fight against tobacco and smoking?
Expert panel: Prof Robert West, Clive Bates, Deborah Arnott (ASH), Prof Jean Francois Etter, Prof Linda Bauld, Lorien Jollye (Vaper and Member of ECCA)

Chair: Prof Ann McNeill

More Info

17.00 Summit close

Speaker Lineup
More Info
Antoine Flahault
Prof. Antoine Flahault

Professor of Public Health, Descartes School of Medicine, Sorbonne Paris Cité, France

  Antoine Flahault, MD, PhD, is professor in public health, at University Descartes, Sorbonne Paris Cité. He has been appointed by Intiative d’Excellence Sorbonne Paris Cité as chair of the Centre Virchow & Villermé for Public Health Paris-Berlin. He co-chairs the European Academic Global Health Alliance, and he is president of the European Agency for…

More Info
robertheadshot1
Prof. Robert West

Professor of Health Psychology and Director of Tobacco Studies at Cancer Research UK

Robert  West is Professor of Health Psychology and Director of Tobacco Studies at the Cancer Research UK Health Behaviour Research Centre, University College London, UK. Professor West is also co-director of the National Centre for Smoking Cessation and Training and is Editor-in-Chief of the journal Addiction. He is co-author of the English National Smoking Cessation…

More Info
Portrait JF Etter 20121203 008
Prof. Jean-François Etter

Professor of Public Health, University of Geneva

Professor Jean-François Etter (University of Geneva, Switzerland) has over 18 years of conducting smoking etiology, prevention and cessation research. He has published over 120 scientific articles on smoking cessation trials and various psychological questions related to tobacco dependence and smoking cessation. He is an internationally known expert on e-cigarettes. He has recently published a comprehensive…

More Info
DA
Ms Deborah Arnott

Chief Executive Officer, Action on Smoking (ASH)

Deborah Arnott is a recognised international expert on tobacco control and the WHO Framework Convention on Tobacco Control, with a particular interest in nicotine regulation and harm reduction. She was a member of the NICE Programme Development Group which developed the guidance on tobacco harm reduction and of the Commission on Human Medicines expert advisory…

More Info
jeremy mean
Mr Jeremy Mean

Group Manager, Access & Information for Medicines & Standards, MHRA

Jeremy is a career civil servant and has worked in a range of roles from directly supporting Ministers to policy and management posts in the Department of Health.  Within the MHRA, Jeremy’s current role includes operational policy and delivery through teams covering advertising standards, patient information, legal status of medicines and outreach and education functions. …

More Info